Georges Gemayel Sells 8,787 Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Director Georges Gemayel sold 8,787 shares of the business’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $53.00, for a total transaction of $465,711.00. Following the sale, the director directly owned 27,277 shares of the company’s stock, valued at $1,445,681. This represents a 24.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Georges Gemayel also recently made the following trade(s):

• On Thursday, March 5th, Georges Gemayel sold 10,000 shares of Supernus Pharmaceuticals stock. The shares were sold at an average price of $53.71, for a total transaction of $537,100.00.

Supernus Pharmaceuticals Trading Down 0.9%

SUPN stock opened at $53.67 on Wednesday. Supernus Pharmaceuticals, Inc. has a 12-month low of $29.16 and a 12-month high of $59.68. The business’s 50-day moving average is $51.12 and its 200 day moving average is $48.96. The stock has a market cap of $3.09 billion, a price-to-earnings ratio of -78.93, a PEG ratio of 1.68 and a beta of 0.70.

Analyst Ratings Changes

A number of analysts have recently issued reports on SUPN shares. Wall Street Zen lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 29th. Craig Hallum set a $65.00 target price on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 25th. Zacks Research lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, January 29th. Finally, Stifel Nicolaus increased their target price on shares of Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research report on Friday, December 19th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $62.17.

Institutional Trading of Supernus Pharmaceuticals

Several hedge funds have recently made changes to their positions in SUPN. Hantz Financial Services Inc. raised its position in shares of Supernus Pharmaceuticals by 81.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 281 shares during the period. Torren Management LLC purchased a new position in Supernus Pharmaceuticals in the fourth quarter worth approximately $49,000. USA Financial Formulas purchased a new position in Supernus Pharmaceuticals in the third quarter worth approximately $50,000. EverSource Wealth Advisors LLC purchased a new position in Supernus Pharmaceuticals in the second quarter worth approximately $51,000. Finally, Smartleaf Asset Management LLC increased its stake in Supernus Pharmaceuticals by 30.8% during the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock worth $54,000 after acquiring an additional 268 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.